Coumadin

(Warfarin)

ApprovedSmall molecule

Warfarin is a blood thinner used to prevent blood clots that could cause strokes, heart attacks, or other serious conditions. It's commonly prescribed to patients with irregular heartbeat, those who have had blood clots, or people with certain heart valve replacements.[2] Coumadin is currently approved and in use across 63 indications[4].[1]

Coumadin is one of 1171 small molecule programs targeting Thrombophlebitis. It is currently in Approved.

Indications

314

Total Trials

Active Trials

1,170

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

ThrombophlebitisApproved

CalcificationActive, not recruiting

Cirrhosis of LiverApproved

Cardiovascular DiseaseApproved

MetastasisApproved

Atrial FlutterApproved

Heart Valve DiseaseApproved

Essential HypertensionApproved

Venous ThromboembolismApproved

Thrombotic DiseaseActive, not recruiting

ThrombophlebitisApproved

Approved

CalcificationApproved

Active, not recruiting

Cirrhosis of LiverApproved

Approved

Cardiovascular DiseaseApproved

Approved

MetastasisApproved

Approved

Atrial FlutterApproved

Approved

Heart Valve DiseaseApproved

Approved

Essential HypertensionApproved

Approved

Venous ThromboembolismApproved

Approved

Thrombotic DiseaseApproved

Active, not recruiting

Showing 10 of 62 indications

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Coumadin

AAbbott

Approved

2 2

Mekinist

Novartis

Preclinical

3 3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 4

Duragesic

CCephalon

Preclinical

1 5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Prednisone/prednisolone

Roche

Preclinical

3 7

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—8

Osmitrol

BB. Braun Medical Inc.

Preclinical

—9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Bleeding

NCT03636295

Q1 2027

Post-ApprovalRecruiting

Atrial Fibrillation

NCT03862859

Q2 2027

Post-ApprovalRecruiting

Heart Failure

NCT06655376

Q3 2027

Post-ApprovalActive, not recruiting

Atrial Fibrillation

NCT04045093

Clinical

Trials by Indication[1]

Atrial Fibrillation38 trials

The Effect and Safety of Different Intensity Anticoagulation Therapy in Elderly Patients With Non-valvular Atrial Fibrillation

Completed·NNanjing Medical University·Phase 4·NCT01438580·260 enrolled

A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation

Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·N/A·NCT03792152·80 enrolled

Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

Completed· Pfizer logo

Pfizer··NCT05438888·77,814 enrolled

Show 35 more trials

A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01136408·174 enrolled

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Completed· Astellas logo

Astellas·Phase 2·NCT00448214·448 enrolled

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

Terminated· Sanofi logo

Sanofi·Phase 3·NCT00580216·3,773 enrolled

A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation

Completed· Astellas logo

Astellas·Phase 2·NCT00938730·1,280 enrolled

ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)

Completed·UUniversity of Pavia·Phase 4·NCT02935855·300 enrolled

Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis

Completed·UUnity Health Toronto·Phase 2·NCT03987711·151 enrolled

Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation

Terminated·MMayo Clinic·Phase 3·NCT03839355·34 enrolled

Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation

Unknown status·KKorea University Anam Hospital·N/A·NCT01991951·520 enrolled

Evaluation of the WATCHMAN Left Atrial Appendage (LAA) Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy

Completed·BBoston Scientific Corporation·Phase 3·NCT01182441·407 enrolled

Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)

Completed· Bayer logo

Bayer··NCT04249401·134,897 enrolled

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00412984·20,976 enrolled

Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation

Completed·—·Phase 2·NCT02042534·195 enrolled

Dabigatran for Mitral Stenosis Atrial Fibrillation

Active, not recruiting·TThe University of Hong Kong·Phase 4·NCT04045093·370 enrolled

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT02072434·2,199 enrolled

Hirudin Plus Aspirin in the Secondary Prevention of Cardioembolic Stroke Due to Nonvalvular Atrial Fibrillation

Completed·XXijing Hospital··NCT02181361·239 enrolled

Left Atrial Appendage (LAA) Occluders After Catheter Ablation of Atrial Fibrillation

Completed·MMeshalkin Research Institute of Pathology of Circulation·Phase 2·NCT01695824·96 enrolled

Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease

Completed·—·Phase 4·NCT02982850·120 enrolled

Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants

Completed·UUniversity of Sao Paulo General Hospital·Phase 3·NCT03181386·60 enrolled

Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses

Unknown status·RResearch Institute for Complex Problems of Cardiovascular Diseases, Russia·Phase 4·NCT03183843·40 enrolled

The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis

Recruiting·NNicholas Carlson·Phase 4·NCT03862859·718 enrolled

RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial

Completed·HHospital do Coracao·Phase 2·NCT02303795·1,005 enrolled

Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy

Completed·—·Phase 4·NCT03463317·912 enrolled

A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes

Completed· Bayer logo

Bayer··NCT04509193·116,049 enrolled

Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty

Unknown status·—··NCT04878497·1,000,000 enrolled

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Completed· Bayer logo

Bayer·Phase 3·NCT00494871·1,280 enrolled

Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02792335·28,000 enrolled

Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation

Completed·MMassachusetts General Hospital·Phase 3·NCT03702582·100 enrolled

BAY59-7939 Japanese in Atrial Fibrillation (2nd)

Completed· Bayer logo

Bayer·Phase 2·NCT00973323·100 enrolled

Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation

Completed·—·Phase 4·NCT02942407·154 enrolled

Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice

Completed· Bayer logo

Bayer··NCT03847181·45,164 enrolled

A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT03189069·36,000 enrolled

A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT00504556·1,146 enrolled

Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02754154·321,182 enrolled

BAY59-7939 in Atrial Fibrillation Once Daily (OD)

Completed· Bayer logo

Bayer·Phase 2·NCT00973245·102 enrolled

WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation

Completed·BBoston Scientific Corporation·Phase 2/3·NCT00129545·800 enrolled

Interaction16 trials

Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT01657825·20 enrolled

Drug Interaction Study Between AZD3480 and Warfarin

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00689637·26 enrolled

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02783040·13 enrolled

Show 13 more trials

Drug-drug Interaction Study(Lobeglitazone, Warfarin)

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 1·NCT02002611·24 enrolled

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib

Completed·Ppharmaand GmbH·Phase 1·NCT02740712·17 enrolled

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Completed· Astellas logo

Astellas·Phase 1·NCT01911728·14 enrolled

A Drug Interaction Study of Danicopan

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04709094·52 enrolled

A Drug Interaction Study of LY3871801 in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05602675·39 enrolled

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05445232·32 enrolled

Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult Volunteers

Completed·KKowa Research Institute, Inc.·Phase 1·NCT02719431·20 enrolled

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02540668·15 enrolled

Drug Interaction Study of Warfarin and MT-3995

Completed· Tanabe Pharma Corporation logo

Tanabe Pharma Corporation·Phase 1·NCT02531568·20 enrolled

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Completed· Novartis logo

Novartis·Phase 1·NCT02422589·33 enrolled

Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin

Completed·AAkcea Therapeutics·Phase 1·NCT03426033·18 enrolled

Drug Interaction Study of Rifampin and Warfarin in Healthy Volunteers.

Completed·UUniversity of California, San Francisco·N/A·NCT00777855·10 enrolled

Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study

Completed·KKnopp Biosciences·Phase 1·NCT01597310·15 enrolled

Venous Thromboembolism10 trials

Treatment Patterns Among Patients With Venous Thromboembolism in the United States

Completed· Pfizer logo

Pfizer··NCT05795062·13,945 enrolled

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

Completed· LEO Pharma logo

LEO Pharma·Phase 3·NCT01130025·900 enrolled

D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism

Terminated·UUniversità degli Studi dell'Insubria·N/A·NCT00428441·73 enrolled

Show 7 more trials

Prevention of Recurrent Venous Thromboembolism (PREVENT)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000614

Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients

Completed· Bayer logo

Bayer·Phase 3·NCT01516840·60 enrolled

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00680186·2,589 enrolled

Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea

Completed· Pfizer logo

Pfizer··NCT05022563·55,759 enrolled

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

Terminated·—·Phase 4·NCT03196349·44 enrolled

An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism

Completed· Bayer logo

Bayer··NCT06278051·320 enrolled

Odiparcil For The Prevention Of Venous Thromboembolism

Completed· GSK logo

GSK·Phase 2·NCT00244725·961 enrolled

Anticoagulant7 trials

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01431690·52 enrolled

Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04593030·220,518 enrolled

Pleotropic Effect of New Oral Anticoagulants

Unknown status·KKyunghee University Medical Center·Phase 3·NCT02544932·55 enrolled

Show 4 more trials

Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants

Completed·AAzienda Ospedaliera Universitaria Policlinico·Phase 4·NCT00438230·250 enrolled

Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04736719·19,002 enrolled

Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04735523·5,350 enrolled

Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data

Completed·—··NCT04879407·98,947 enrolled

Anticoagulation6 trials

Anticoagulation Regiments in Patients With Prosthetic Heart Valve Thrombosis

Unknown status·KKartal Kosuyolu Yuksek Ihtisas Education and Research Hospital·N/A·NCT02240953·180 enrolled

Anticoagulation for Aortic Bioprosthesis (ANTIPRO)

Completed·IInstituto Nacional de Cirugia Cardiaca, Uruguay·Phase 4·NCT03807921·140 enrolled

Genetic Determinants of Warfarin Anticoagulation Effect

Unknown status·HHadassah Medical Organization·N/A·NCT00162435·500 enrolled

Show 3 more trials

Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service

Completed·—·N/A·NCT02392104·51 enrolled

Anticoagulation Regimens in Pregnant Patients With Prosthetic Heart Valves

Unknown status·KKartal Kosuyolu Yuksek Ihtisas Education and Research Hospital·N/A·NCT02240927·40 enrolled

The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT

Completed·UUniversity of Alberta·Phase 4·NCT02376803·217 enrolled

72 more indications

Tics5 trials

The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects

Completed· Pfizer logo

Pfizer·Phase 1·NCT00914667·14 enrolled

A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir)

Completed· Roche logo

Roche·Phase 4·NCT02780622·20 enrolled

Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Completed·BBial - Portela C S.A.·Phase 1·NCT02779348·16 enrolled

Show 2 more trials

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

Completed·BBial - Portela C S.A.·Phase 1·NCT02169440·20 enrolled

A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT00856570·24 enrolled

Rivaroxaban5 trials

Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis

Terminated·HHospital Geral Roberto Santos·Phase 2/3·NCT03566303·50 enrolled

Rivaroxaban vs. Warfarin in CVT Treatment

Completed·—·Phase 3·NCT04569279·71 enrolled

Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves

Enrolling by invitation·—·Phase 3·NCT07456085·60 enrolled

Show 2 more trials

A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01400646·46 enrolled

Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium

Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 4·NCT02376010·110 enrolled

Venous thrombosis5 trials

Prevention of Venous Thrombosis After Permanent Transvenous Leads Implantation

Completed·UUniversity of Sao Paulo·N/A·NCT00621491·101 enrolled

Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)··NCT00005684

Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study

Unknown status·SSeoul National University Hospital·N/A·NCT01986192·72 enrolled

Show 2 more trials

The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis

Unknown status·—·Phase 3·NCT03217448·80 enrolled

Acute Mesenteric Venous Thrombosis.. in Assiut University Hospital Management Controversies

Unknown status·—·N/A·NCT03483207·30 enrolled

Pulmonary Embolism4 trials

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis

Terminated·SSusan Smyth·Phase 4·NCT02506985·10 enrolled

Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. "PADIS-PE" Study.

Completed·UUniversity Hospital, Brest·Phase 3·NCT00740883·374 enrolled

Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy

Unknown status·MMeshalkin Research Institute of Pathology of Circulation·Phase 4·NCT02979561·200 enrolled

Show 1 more trial

STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism

Unknown status·UUniversity of Birmingham·Phase 3·NCT04727437·1,466 enrolled

Trial3 trials

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00235248·350 enrolled

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Terminated·AArtivion Inc.·Phase 3·NCT04142658·863 enrolled

Arterial Disease Multifactorial Intervention Trial (ADMIT)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000539

Knee Replacement Surgery3 trials

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT00097357·1,238 enrolled

A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery

Completed· Astellas logo

Astellas·Phase 2·NCT00595426·685 enrolled

Prophylaxis Against DVTs After Primary Hip and Knee Replacement Surgery

Unknown status·TThe New England Baptist Hospital·N/A·NCT00767559·330 enrolled

Midazolam3 trials

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02345304

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02617810·18 enrolled

A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects

Completed· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 1·NCT05480488·18 enrolled

Antiphospholipid Syndrome3 trials

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

Completed·—·Phase 4·NCT02295475·48 enrolled

Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE

Recruiting·SSeoul National University Hospital·Phase 4·NCT05995600·200 enrolled

RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome

Unknown status·UUniversity College, London·Phase 2·NCT03684564·43 enrolled

Deep Vein Thrombosis3 trials

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00643201·5,614 enrolled

AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients

Completed· Pfizer logo

Pfizer·Phase 3·NCT01780987·80 enrolled

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT00216866·70 enrolled

Treatment3 trials

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT01561937·127 enrolled

Treatment for Blood Clots in the Veins of the Legs

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00001713·20 enrolled

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT00986154·8,292 enrolled

Portal vein thrombosis2 trials

TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV

Unknown status·ZZaibo Jiang·Phase 3·NCT02853526·100 enrolled

Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）

Completed·NNorthern Jiangsu People's Hospital·Phase 4·NCT04645550·120 enrolled

Prostate Cancer2 trials

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00014352

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00004054·397 enrolled

Safety and Efficacy2 trials

Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial

Unknown status·PPeshawar Institute of Cardiology·Phase 4·NCT05973188·141 enrolled

Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy

Completed·YYasser Elnahas·Phase 3·NCT01758640·200 enrolled

ART2 trials

Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02161731·24 enrolled

A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01825876·17 enrolled

Effectiveness2 trials

Comparative Effectiveness and Safety Between Warfarin and Dabigatran

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03254134·22,490 enrolled

The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis

Completed·AAbu Dhabi Health Services Company··NCT06606275·67 enrolled

Atopic Dermatitis2 trials

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Completed· LEO Pharma logo

LEO Pharma·Phase 1·NCT03556592·40 enrolled

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

Completed· Regeneron logo

Regeneron·Phase 1·NCT02647086·14 enrolled

Stroke2 trials

Aspirin Or Warfarin To Prevent Stroke

Terminated·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 3·NCT00004728

PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01227629·502 enrolled

After Cardiac Surgery2 trials

The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery

Active, not recruiting·SSt. Paul's Hospital, Canada·Phase 2·NCT05006287·100 enrolled

DOAC Versus VKA After Cardiac Surgery

Withdrawn·LLaval University·Phase 2·NCT04002011

Coronary Artery Bypass2 trials

Post Coronary Artery Bypass Graft (CABG) Study

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000463

Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery

Unknown status·UUniversity of Sao Paulo General Hospital·Phase 4·NCT05300555·50 enrolled

Left Ventricular Thrombus2 trials

Rivaroxaban in Left Ventricular Thrombus

Completed·NNational Institute of Cardiovascular Diseases, Pakistan·Phase 4·NCT04970576·261 enrolled

Apixaban in Patients With Left Ventricular Thrombus

Completed·SSaud Al Babtain Cardiac Center·Phase 3·NCT05208398·50 enrolled

Monotherapy2 trials

Anti-thrombotic Monotherapy With the HeartMate 3 LVAS

Unknown status·IInstitute for Clinical and Experimental Medicine·N/A·NCT03704220·10 enrolled

Anti-thrombotic Monotherapy in HeartMate 3 Left Ventricular Assist System (LVAS)

Unknown status·IInstitute for Clinical and Experimental Medicine·N/A·NCT03781258·20 enrolled

Gastric Emptying2 trials

Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

Completed·FFujian Shengdi Pharmaceutical Co., Ltd.·Phase 1·NCT06723691·57 enrolled

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

Completed·IIntarcia Therapeutics·Phase 1·NCT02641899·33 enrolled

Ischemic stroke1 trial

Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke

Unknown status·—·Phase 1·NCT01518231·40 enrolled

Pancreatic Cancer1 trial

Biological Effect of Warfarin on Pancreatic Cancer

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT03536208

Dapagliflozin1 trial

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00904176·30 enrolled

Overweight or Obese1 trial

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05815680·48 enrolled

MPA1 trial

Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02183389·18 enrolled

Mitral Valve Repair1 trial

Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair

Recruiting·GGuangdong Provincial People's Hospital·Phase 4·NCT06738992·384 enrolled

Efficacy and Safety1 trial

Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)

Completed·YYonsei University·Phase 3·NCT03244319·220 enrolled

Thrombocytopenia1 trial

Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

Terminated·UUniversity of Louisville·Phase 2·NCT00673439·3 enrolled

ARDS1 trial

Assessment of 2012 Bioequivalence Standards for Warfarin

Completed·UUniversity of California, San Francisco·Phase 1·NCT02574754·10 enrolled

Adult Subject1 trial

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03363815·56 enrolled

Catheter1 trial

Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters

Completed·CCancer Research Campaign Clinical Trials Centre·N/A·NCT00024297

Prosthetic Valve Thrombosis1 trial

Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation

Recruiting·—·N/A·NCT02318342·3,000 enrolled

Idiopathic Pulmonary Fibrosis1 trial

AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis

Terminated·—·Phase 3·NCT00957242·145 enrolled

TIA1 trial

Validation of Predictors of OAC Initiation Using EMR Data

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03006341·140,187 enrolled

Post-Operative Atrial Fibrillation1 trial

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

Completed·SSanford Health·Phase 2/3·NCT02889562·56 enrolled

Hemorrhage1 trial

Hemorrhage Following Small Polyp Resection in the Colon in Anticoagulated Patients

Unknown status·HHadassah Medical Organization·N/A·NCT02375646·286 enrolled

Oral1 trial

Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices

Completed·PPalak Shah·Phase 2·NCT04865978·30 enrolled

Prospective1 trial

Evaluation of Maintenance Dosing vs Loading Dosing Upon Restarting Warfarin Therapy: A Prospective Randomized Trial

Completed·UUniversity of Alberta·Phase 1·NCT01124058·39 enrolled

Heart Failure1 trial

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device

Recruiting·—·Phase 4·NCT06655376·128 enrolled

Calcification1 trial

Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 4·NCT02090075·66 enrolled

AML1 trial

An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates

Active, not recruiting· Sanofi logo

Sanofi·Phase 1·NCT06686628·23 enrolled

Complication1 trial

Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.

Active, not recruiting·PPetrovsky National Research Centre of Surgery··NCT07358416·500 enrolled

Pulmonary Hypertension1 trial

Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT01036802·3 enrolled

Factor Xa Inhibitor1 trial

Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

Completed·PPortola Pharmaceuticals·Phase 2·NCT00742859·508 enrolled

Semaglutide1 trial

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT02070510·52 enrolled

Alveolar Soft Part Sarcoma1 trial

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01391962·34 enrolled

Drug1 trial

A Drug Drug Interaciton Study of Imrecoxib and Warfarin in Healthy Volunteers

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02426060·12 enrolled

Elderly Patients1 trial

Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity

Unknown status·UUniversity of Campania Luigi Vanvitelli··NCT02069132·376 enrolled

Haemodialysis1 trial

Access II - Trial of Warfarin to Prevent Malfunction of Haemodialysis Catheters

Completed·HHamilton Health Sciences Corporation·Phase 3·NCT00157651·170 enrolled

Patients With Advanced Solid Tumors1 trial

Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT00091299·24 enrolled

Solid Tumors1 trial

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT01340846·48 enrolled

Rheumatoid Arthritis1 trial

A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01636557·12 enrolled

Esmolol1 trial

Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03347968·22 enrolled

Cohort Study1 trial

Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea

Completed· Pfizer logo

Pfizer··NCT03572972·64,684 enrolled

Chronic Obstructive Pulmonary Disease1 trial

The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism

Unknown status·—·N/A·NCT03185845·392 enrolled

Overweight1 trial

A Study of BGM0504 in Overweight or Obese Participants

Completed·BBrightGene Bio-Medical Technology Co., Ltd.·Phase 1·NCT06920056·28 enrolled

Antiplatelet Therapy1 trial

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

Completed·AAbbott Medical Devices·Phase 4·NCT02836652·72 enrolled

Coagulation1 trial

Tecarfarin Anti-Coagulation Trial (TACT)

Unknown status·EEspero Biopharma·Phase 3·NCT02522221·1,000 enrolled

Empagliflozin1 trial

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

Recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT07331389·111 enrolled

AIN1 trial

The Study of Warfarin Maintenance Dose in Chinese Patients

Unknown status·—··NCT01855737·1,000 enrolled

Antiplatelet1 trial

Warfarin and Antiplatelet Vascular Evaluation

Unknown status·—·Phase 3·NCT00125671·2,400 enrolled

Pilot Study1 trial

Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection

Withdrawn·UUniversity of California, San Diego·Phase 1·NCT00265408

Direct Oral Anticoagulants (DOACs)1 trial

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Completed·AAlliance Foundation Trials, LLC.·N/A·NCT02744092·811 enrolled

Patent foramen ovale1 trial

Patent Foramen Ovale in Cryptogenic Stroke Study

Completed·—·Phase 4·NCT00697151·630 enrolled

Left Atrial Appendage Closure1 trial

Left Atrial Appendage Closure Compared to Standard Antiplatelet Therapy in Patients With AF Who Underwent PCI

Unknown status·MMeshalkin Research Institute of Pathology of Circulation·Phase 2·NCT02492230·50 enrolled

Thrombosis1 trial

Treatment of Upper Extremity Deep-Vein Thrombosis

Completed·UUniversity of Oklahoma·Phase 4·NCT00245856·67 enrolled

Bleeding1 trial

Low INR to Minimize Bleeding With Mechanical Valves Trial

Recruiting·PPopulation Health Research Institute·Phase 3·NCT03636295·2,625 enrolled

Psoriasis1 trial

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02397382·16 enrolled

Metachromatic Leukodystrophy1 trial

Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy

Completed·TThe Cooper Health System·N/A·NCT00683189·10 enrolled

Unspecified13 trials

Medical Need of OAC Reversal

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03254147·53,969 enrolled

A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT02252731·22 enrolled

Duloxetine - Warfarin Pharmacodynamic Study

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT00533026·60 enrolled

Show 10 more trials

Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

Completed· Altimmune logo

Altimmune·Phase 1·NCT04972396·40 enrolled

Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus

Completed·HHadassah Medical Organization·Phase 3·NCT03232398·40 enrolled

RIvoraxaban in Mitral Stenosis

Terminated·RRajaie Cardiovascular Medical and Research Center·Phase 3·NCT03926156·40 enrolled

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Completed·BBial - Portela C S.A.·Phase 1·NCT02287415·13 enrolled

BAY73-4506 Probe Substrate Study

Completed· Bayer logo

Bayer·Phase 1·NCT01287598·41 enrolled

Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients

Completed·HHamilton Health Sciences Corporation·Phase 2·NCT00814177·160 enrolled

Warfarin Patient Self-Monitoring

Completed·UUniversity of British Columbia·N/A·NCT00925028·25 enrolled

Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR

Not yet recruiting·MMeshalkin Research Institute of Pathology of Circulation·Phase 3·NCT07434661·120 enrolled

A Study of LY2216684 and Warfarin in Healthy Subjects

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01263119·18 enrolled

Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information

Completed·—·N/A·NCT00401414·344 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

ATHROMBIN

NDA NDA011771

Jan 1, 1982

PANWARFIN

NDA NDA017020

Feb 7, 1995

COUMADIN

NDA NDA009218

Sources

References

[1]
ClinicalTrials.gov — 314 trial records for Warfarin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Coumadin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Warfarin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Warfarin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA009218). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Abbott company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Vitamin K Epoxide Reductase Complex Subunit 1 Isoform 1 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AAbbott